Overview

This trial is active, not recruiting.

Conditions functional gastrointestinal disorders, lactose intolerance, fructose intolerance
Treatment no intervention: observational study
Sponsor Brain-Gut Research Group
Start date March 2014
End date December 2018
Trial size 3000 participants
Trial identifier NCT02085889, BGRG-2415b

Summary

Background: The association of fructose and lactose intolerance and malabsorption with the symptoms of different functional gastrointestinal disorders (FGID) is unclear. The mechanisms behind the multi-organ symptoms remain unclear. Both FGID and saccharide intolerances are common (>10% of any given population). Dietary modification based on intolerance diagnostics could provide an effective treatment for FGID, which are otherwise difficult to treat.

Aim: To investigate the prevalence and interrelationships of fructose and lactose intolerance (symptom induction) and malabsorption (breath test gas production) and their association with clinical GI as well as non-GI symptoms in FGID and the outcome of standard dietary intervention. Mechanisms related to symptom genesis will be investigated using metabolomic analysis of plasma and urine by gas chromatography/time-of-flight mass spectrometry (GC/TOFMS).

Methods: Fructose and lactose intolerance (defined by positive symptom index) and malabsorption (defined by increased hydrogen/methane) will be determined in successive male and female FGID patients in a single center using breath-testing. Symptoms will be recorded using standardised questionnaires and the Rome III criteria. The prevalence of the intolerances in the different FGID subgroups and the associations between breath testing results, clinical symptoms and the outcome of dietary modification will be assessed. Factors predictive of the outcome of dietary modulation will be screened for. GC/TOFMS will be used to assess the human and microbial metabolome in urine and plasma.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
lactose intolerance fructose intolerance neither intolerance
no intervention: observational study

Primary Outcomes

Measure
Number with adequate symptom relief
time frame: 6-12 weeks

Secondary Outcomes

Measure
Association between adequate symptom relief and test variables
time frame: 6-12 weeks

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion criteria: - Patients with functional GI disorders according to ROME 3 criteria - Without evidence of organic disease by standardised testing in GI practice. Exclusion criteria: - Current or relevant history of organic disease.

Additional Information

Official title Fructose and Lactose Intolerance and Malabsorption: the Relationship Between Metabolism and Symptoms in Functional Gastrointestinal Disorders
Principal investigator Clive Wilder-Smith, MD
Trial information was received from ClinicalTrials.gov and was last updated in July 2015.
Information provided to ClinicalTrials.gov by Brain-Gut Research Group.